Phaseline

Companies › BlueSky Immunotherapies

BlueSky Immunotherapies: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FluBHPVE6E7
Live attenuated influenza virus expressing HPV16 E6 and E7 therapeutic vaccine
–Phase 1HPV Infection; Oropharyngeal Squamous Cell Carcinoma (SCC)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05829629FluBHPVE6E7Phase 1HPV InfectionInfectious diseaseSep 2025
NCT06589609FluBHPVE6E7Phase 1Oropharyngeal Squamous Cell Carcinoma (SCC)OncologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.